Our own studies have demonstrated the capacity of an anti-FRα IgE antibody (MOv18) to restrict tumour growth in several model systems and to recruit monocytes and macrophages against tumours, supporting the progress of this agent to a first-in-class Phase I clinical trial in oncology (NCT02546921, www.clinicaltrials.gov). This evidence concerns the gene FOLR1 and neoplasm.